Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat EstimatesZacks Investment Research • 08/06/24
How These Two Lesser-Known Biotech Names Obliterated Sales ExpectationsInvestors Business Daily • 08/06/24
Curious about Halozyme Therapeutics (HALO) Q2 Performance? Explore Wall Street Estimates for Key MetricsZacks Investment Research • 08/05/24
How Small Biotech Halozyme, With A 41% Run, Is Getting Under Your SkinInvestors Business Daily • 07/03/24
Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple SclerosisPRNewsWire • 06/25/24
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating PolyneuropathyPRNewsWire • 06/21/24
Halozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/06/24
Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial OutlookPRNewsWire • 06/06/24
Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery PlatformPRNewsWire • 06/05/24
Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferencePRNewsWire • 06/04/24